Cargando…

Pharmacokinetics and pharmacodynamics of propofol in cancer patients undergoing major lung surgery

Despite the growing number of cancer cases and cancer surgeries around the world, the pharmacokinetics (PK) and pharmacodynamics (PD) of anesthetics used in this population are poorly understood. Patients operated due to cancer are usually in severe state and often require chemotherapy. It might aff...

Descripción completa

Detalles Bibliográficos
Autores principales: Przybyłowski, Krzysztof, Tyczka, Joanna, Szczesny, Damian, Bienert, Agnieszka, Wiczling, Paweł, Kut, Katarzyna, Plenzler, Emilia, Kaliszan, Roman, Grześkowiak, Edmund
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355445/
https://www.ncbi.nlm.nih.gov/pubmed/25628234
http://dx.doi.org/10.1007/s10928-015-9404-6
_version_ 1782360856579801088
author Przybyłowski, Krzysztof
Tyczka, Joanna
Szczesny, Damian
Bienert, Agnieszka
Wiczling, Paweł
Kut, Katarzyna
Plenzler, Emilia
Kaliszan, Roman
Grześkowiak, Edmund
author_facet Przybyłowski, Krzysztof
Tyczka, Joanna
Szczesny, Damian
Bienert, Agnieszka
Wiczling, Paweł
Kut, Katarzyna
Plenzler, Emilia
Kaliszan, Roman
Grześkowiak, Edmund
author_sort Przybyłowski, Krzysztof
collection PubMed
description Despite the growing number of cancer cases and cancer surgeries around the world, the pharmacokinetics (PK) and pharmacodynamics (PD) of anesthetics used in this population are poorly understood. Patients operated due to cancer are usually in severe state and often require chemotherapy. It might affect the PK/PD of drugs used in this population. Therefore, in this study we explored the PK/PD of propofol in cancer patients having a major lung surgery. 23 patients that underwent a propofol–fentanyl total intravenous anesthesia were included in the analysis. A large set of demographic, biochemical and hemodynamic parameters was collected for the purpose of covariate analysis. Nonlinear mixed effect modeling in NONMEM was used to analyze the collected data. A three-compartment model was sufficient to describe PK of propofol. The anesthetic effect (AAI index) was linked to the propofol effect site concentrations through a sigmoidal E (max) model. A slightly higher value of clearance, a lower value of distribution clearance, and a decreased volume of peripheral compartment were observed in our patients, as compared with the literature values reported for healthy volunteers by Schnider et al. and by Eleveld et al. Despite these differences, both models led to a clinically insignificant bias of −8 and −1 % in concentration predictions, as reflected by the median performance error. The C (e50) and propofol biophase concentration at the time of postoperative orientation were low and equaled 1.40 and 1.13 mg/L. The population PK/PD model was proposed for cancer patients undergoing a major lung surgery. The large body of studied covariates did not affect PK/PD of propofol significantly. The modification of propofol dosage in the group of patients under study is not necessary when TCI-guided administration of propofol by means of the Schnider model is used. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10928-015-9404-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4355445
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-43554452015-03-13 Pharmacokinetics and pharmacodynamics of propofol in cancer patients undergoing major lung surgery Przybyłowski, Krzysztof Tyczka, Joanna Szczesny, Damian Bienert, Agnieszka Wiczling, Paweł Kut, Katarzyna Plenzler, Emilia Kaliszan, Roman Grześkowiak, Edmund J Pharmacokinet Pharmacodyn Original Paper Despite the growing number of cancer cases and cancer surgeries around the world, the pharmacokinetics (PK) and pharmacodynamics (PD) of anesthetics used in this population are poorly understood. Patients operated due to cancer are usually in severe state and often require chemotherapy. It might affect the PK/PD of drugs used in this population. Therefore, in this study we explored the PK/PD of propofol in cancer patients having a major lung surgery. 23 patients that underwent a propofol–fentanyl total intravenous anesthesia were included in the analysis. A large set of demographic, biochemical and hemodynamic parameters was collected for the purpose of covariate analysis. Nonlinear mixed effect modeling in NONMEM was used to analyze the collected data. A three-compartment model was sufficient to describe PK of propofol. The anesthetic effect (AAI index) was linked to the propofol effect site concentrations through a sigmoidal E (max) model. A slightly higher value of clearance, a lower value of distribution clearance, and a decreased volume of peripheral compartment were observed in our patients, as compared with the literature values reported for healthy volunteers by Schnider et al. and by Eleveld et al. Despite these differences, both models led to a clinically insignificant bias of −8 and −1 % in concentration predictions, as reflected by the median performance error. The C (e50) and propofol biophase concentration at the time of postoperative orientation were low and equaled 1.40 and 1.13 mg/L. The population PK/PD model was proposed for cancer patients undergoing a major lung surgery. The large body of studied covariates did not affect PK/PD of propofol significantly. The modification of propofol dosage in the group of patients under study is not necessary when TCI-guided administration of propofol by means of the Schnider model is used. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10928-015-9404-6) contains supplementary material, which is available to authorized users. Springer US 2015-01-28 2015 /pmc/articles/PMC4355445/ /pubmed/25628234 http://dx.doi.org/10.1007/s10928-015-9404-6 Text en © The Author(s) 2015 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Paper
Przybyłowski, Krzysztof
Tyczka, Joanna
Szczesny, Damian
Bienert, Agnieszka
Wiczling, Paweł
Kut, Katarzyna
Plenzler, Emilia
Kaliszan, Roman
Grześkowiak, Edmund
Pharmacokinetics and pharmacodynamics of propofol in cancer patients undergoing major lung surgery
title Pharmacokinetics and pharmacodynamics of propofol in cancer patients undergoing major lung surgery
title_full Pharmacokinetics and pharmacodynamics of propofol in cancer patients undergoing major lung surgery
title_fullStr Pharmacokinetics and pharmacodynamics of propofol in cancer patients undergoing major lung surgery
title_full_unstemmed Pharmacokinetics and pharmacodynamics of propofol in cancer patients undergoing major lung surgery
title_short Pharmacokinetics and pharmacodynamics of propofol in cancer patients undergoing major lung surgery
title_sort pharmacokinetics and pharmacodynamics of propofol in cancer patients undergoing major lung surgery
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355445/
https://www.ncbi.nlm.nih.gov/pubmed/25628234
http://dx.doi.org/10.1007/s10928-015-9404-6
work_keys_str_mv AT przybyłowskikrzysztof pharmacokineticsandpharmacodynamicsofpropofolincancerpatientsundergoingmajorlungsurgery
AT tyczkajoanna pharmacokineticsandpharmacodynamicsofpropofolincancerpatientsundergoingmajorlungsurgery
AT szczesnydamian pharmacokineticsandpharmacodynamicsofpropofolincancerpatientsundergoingmajorlungsurgery
AT bienertagnieszka pharmacokineticsandpharmacodynamicsofpropofolincancerpatientsundergoingmajorlungsurgery
AT wiczlingpaweł pharmacokineticsandpharmacodynamicsofpropofolincancerpatientsundergoingmajorlungsurgery
AT kutkatarzyna pharmacokineticsandpharmacodynamicsofpropofolincancerpatientsundergoingmajorlungsurgery
AT plenzleremilia pharmacokineticsandpharmacodynamicsofpropofolincancerpatientsundergoingmajorlungsurgery
AT kaliszanroman pharmacokineticsandpharmacodynamicsofpropofolincancerpatientsundergoingmajorlungsurgery
AT grzeskowiakedmund pharmacokineticsandpharmacodynamicsofpropofolincancerpatientsundergoingmajorlungsurgery